
Target the Repair Pathway. Not the Trip.


Investor Overview: Unlocking the scalable future of CNS therapeutics.




Preclinical CNS Biotechnology · XYCO-02 & XYCO-01

Decoupling the psychedelic experience from neurological repair creates a paradigm shift in scale

A game-changer for PTSD, mTBI, and neurodegeneration.



The therapeutic delivery model is broken.



Supervised Psychedelic Sessions

- Relies on the subjective trip.
- Requires 6-to-8-hour supervised clinical monitoring.
- Limits patient access and restricts commercial scalability.



A Different Setting for Treatment


- Targeting the underlying repair mechanism.
- Sub-perceptual dose intended to produce no noticeable psychedelic effects.
- Administered routinely at home.

The Commercial Paradigm Shift


	Standard Psychedelic Model	Xycota Precision Model
Setting	Supervised Clinic	**At-Home Routine**
Dose	Macrodose (Hallucinogenic)	**Sub-perceptual (Non-hallucinogenic)**
Primary Target	5-HT2A (Trip)	**TrkB (Repair)**
Efficacy Readout	Subjective Patient Experience	**Clinical Score + Serum BDNF**
Market Ceiling	Niche, High-Cost, Logistically Constrained	**Broad, Scalable, Blockbuster Potential**

You do not need the trip to get the neurological repair.

Psilocybin triggers two distinct pathways. The repair pathway can be isolated.




Memory rescue depends entirely on TrkB, not 5-HT2A.



Psychedelic Receptor Blocked

Psilocybin + M100907 5-HT2A antagonist

Result: Memory rescue remained.



Neurotrophic Receptor Blocked

Psilocybin + ANA-12 TrkB blocker

Result: Memory rescue disappeared.

Methodology: Repeated low-dose oral psilocybin (0.1 mg/kg every other day) normalized prefrontal signaling.

Source: Ascone et al., Neuropsychopharmacology 2026; 51(8):1454-1463



XYCO-02: Lead Candidate for Mild PTSD

Sub-perceptual oral psilocybin capsule.

Formulation:
Standardized, low-dose oral regimen.

Design Goal:
Stay below the threshold of noticeable psychedelic effects.

Application:
At-home, daily/routine administration.

Status:
Preclinical.

Proposed 28-Day At-Home Clinical Architecture

Double-blind, placebo-controlled study in adults with mild PTSD.



Health Canada CTA in preparation.

Managed in partnership with CRO KGK Science.

Answering the critical question: Can participants with mild PTSD distinguish XYCO-02 from placebo during repeated dosing?

Dual Readouts: Proving the mechanism in humans



Clinical Symptom Score (CAPS-5)

- Assesses whether PTSD symptoms improve compared with matched placebo

+



Supporting Blood Readout (Serum BDNF)

- Measures the brain repair pathway from a peripheral blood draw


=

Mechanism Validated

A blood change alone does not prove repair. But correlated with CAPS-5 improvement, it validates the TrkB mechanism in humans.


PTSD is the wedge. The mechanism applies to massive unmet CNS markets.

If XYCO-02 proves that low-dose psilocybin activates TrkB without the trip, it unlocks a scalable platform for trauma-based and neurodegenerative brain disorders.



XYCO-01: Exosome-Encapsulated Psilocin for FTD

Pushing compounds deeper into the CNS.



Indication: Frontotemporal Dementia (FTD).

Regulatory: FDA Orphan Drug Designation application filed (under review).

Next Step: Preclinical animal study following XYCO-02 advancement.

Leveraging specialized exosome and liposome formulation expertise.

The Architects Behind the Science

Dr. Marvin S. Hausman, MD
(Chief Scientific Officer)

- Immunologist, board-certified surgeon, former NIH Surgeon.
- 35+ years in CNS and clinical drug development.
- Co-author of the foundational 2026 Fragile X study.

Brad Listermann
(CEO)

- Corporate strategy, IP, and capital formation leader.
- Tech entrepreneur and inventor (AI, cybersecurity patents).
- 20+ years of capital-markets leadership.

Dr. Anthony Smith, PhD
(Sr. Lab Operations Manager)

- Exosome and liposome formulation expert.
- Former President/CSO of EVIO Labs.
- PhD in Molecular and Cellular Biology.

World-Class Validation Partners

Roma Tre University

Assoc. Prof. Viviana Trezza, PhD

- Senior author of the foundational 2026 Fragile X pharmacology study.

Baylor College of Medicine

Dr. Louise Hecker, PhD

- Senior author of the 2025 npj Aging study on psilocin and cellular survival.

KGK Science

Andrew Charrette, MSc (Director of Regulatory Affairs)

- CRO partner executing the Health Canada CTA preparation for XYCO-02.

Upcoming Milestones & Valuation Catalysts

Finalize and submit Health Canada CTA for XYCO-02 (Mild PTSD).

FDA ruling on Orphan Drug Designation for XYCO-01 (FTD).

Initiation of the 28-day human clinical trial (XYCO-02).

Preclinical FTD animal study launch (XYCO-01).

Market Potential & Investor Opportunity

- XYCO-02 (Mild PTSD): Addressable Market of ~13M US Adults with PTSD (Unmet Need).
- XYCO-01 (FTD): Orphan Drug Designation Pathway; High Value in Rare Neurodegenerative Disease.
- **Combined TAM:** Multi-Billion Dollar Opportunity in CNS Repair.

Institutional Data Room currently open for qualified strategic partners and investors.


Target the Repair. Not the Trip.

The Assets:

XYCO-02 (Oral Capsule)
& XYCO-01 (Exosome)

The Opportunity:

Scalable, at-home CNS repair for PTSD, mTBI, and FTD



Qualified Institutions:
Request Data Room Access
xycota.com/investors

All programs are investigational and preclinical. Statements involve forward-looking risks.